SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies0-9A BC DE FGH IJ KL MN OP QR ST UV WX YZ
Browse current Australian managed funds0-9A BCDE FGH IJKL MNOP QRST UVWX YZ

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

BIOXYNE LIMITED (BXN)

Listed on ASX

SHARE PRICES

(updated weekly)

Former (or subsequent) names

 FROMTO
BIOXYNE LIMITED10/04/2012
PROBIOMICS LIMITED02/05/200510/04/2012
VRI BIOMEDICAL LIMITED02/05/2005

Shareholder links

Our website ranking of BXN: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Security Transfer Australia Pty Ltd, 770 Canning Highway Applecross WA 6153

Tel : +61 3 9628 2200
Fax : +61 8 9315 2233
RegistryWebsite RegistryEmail

Company details

Address: Suite 506  Level 5, 50 Clarence Street  Sydney NSW 2000
Tel:  + 61 2 9078 8180 Fax: + 61 2 9078 7661

Date first listed: 14/12/2000
Company Secretary: Guy Robertson
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Biotechnology

The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of an underwritten share placement. Security Code: BXN

20/02/2013

The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of an underwritten share placement to assist with transaction costs following the entry into a conditional non-binding proposal to acquire Vitality Devices Pty Limited. Security Code: BXN

20/02/2013

The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the results and data from its independent clinical research organisation.

28/06/2012

company advises that its Fully Paid Ordinary shares will remain in suspension until the results of the clinical trials are fully assessed. The Company has received both the initial results and further very detailed analyses of the data. The analysis is ongoing and now requires professional validation. The Company believes that it will be in a position to release a detailed announcement after this review on Wednesday, 27 June 2012

25/06/2012

The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to the results and data from its independent clinical research organisation which are continuing to be assessed.

15/06/2012

name changed from Probiomics Limited

10/04/2012

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    07/10/2019Anthony Ho525,000$0.021$11,025
    31/05/2019Anthony Ho800,000$0.017$13,600
    11/10/2018Anthony Ho453,567$0.029$13,244
    02/08/2018Anthony Ho300,000$0.043$12,780
    11/07/2018Anthony Ho130,000$0.049$6,357

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Anthony HoNon Exec Chairman12/11/2012
    Guy RobertsonCFO, COO01/09/2016
    Patrick FordNon Exec Director20/05/2005
    Peter Hughes-HallettNon Exec Director01/05/2018
    NH ChuaDirector, CEO19/04/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Max ParkinDirector13/06/201717/01/2019
    Peter FrenchExecutive Director15/02/201615/02/2018
    George Cameron-DowNon Exec Director21/07/201418/11/2016
    Jarrod WhiteCFO18/02/201301/09/2016
    Jeremy CookNon Exec Director13/12/201221/07/2014
    Phillip ComansCEO12/12/201202/12/2013
    Ashok JairathCFO27/07/200718/02/2013
    David RadfordManaging Director04/04/201212/12/2012
    Ian MuttonChairman04/04/201229/11/2012
    William HarrisonDirector04/04/201229/11/2012
    Glenn CrispNon Exec Director30/10/2012
    Douglas WilsonDirector17/04/201226/10/2012
    Simon TaylorNon Exec Director25/07/200804/04/2012
    Simon O'LoughlinNon Exec Director31/07/200804/04/2012
    Bradley WalshNon Exec Director07/08/2008
    Ronald PennyNon Exec Director18/02/200506/08/2008
    Bryan GardinerNon Exec Chairman18/02/200523/06/2008
    Kim SlatyerCEO11/03/2008
    Victor GarlandNon Exec Chairman18/02/200520/05/2005
    Geoffrey WildNon Exec Director07/11/200318/05/2005
    Sally CappNon Exec Director29/05/200326/11/2004
    James GrantChairman29/05/200304/07/2004
    Ronald RowlandNon Exec Director29/05/200330/06/2004
    Glyn TongeNon Exec Director10/09/200127/11/2003
    Ronald DeaneChairman24/04/200303/11/2003
    Jack CadeNon Exec Director01/11/200003/11/2003
    Kenneth BaxterNon Exec Director01/11/200029/05/2003
    Leon IvoryExecutive Director29/05/2003
    Robert ClancyNon Exec Director29/05/200118/07/2002

    Date of first appointment, title may have changed.